Dimensional Fund Advisors’s MoonLake Immunotherapeutics MLTX Stock Holding History

Dimensional Fund Advisors’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$490K	Sell	26,307 -157,245	-86%	-$2.6M	﹤0.01%	2945
2025 Q4	$2.42M	Buy	183,552 +172,550	+1,568%	+$2.04M	﹤0.01%	2698
2025 Q3	$78.9K	Sell	11,002 -41,717	-79%	-$2.17M	﹤0.01%	3213
2025 Q2	$2.49M	Sell	52,719 -775	-1%	-$31.6K	﹤0.01%	2708
2025 Q1	$2.09M	Sell	53,494 -10,890	-17%	-$469K	﹤0.01%	2715
2024 Q4	$3.49M	Buy	+64,384	New	+$3.29M	﹤0.01%	2640

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Dimensional Fund Advisors's MLTX Position: Q1 2026 in Review

Dimensional Fund Advisors reduced its MoonLake Immunotherapeutics (MLTX) stake by 86% in Q1 2026, selling an estimated $2.6M and leaving 26,307 shares worth $490K. The position accounts for ﹤0.01% of the portfolio, ranked #2945.

Dimensional Fund Advisors first reported a position in MLTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $3.49M in Q4 2024. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

Dimensional Fund Advisors held 26,307 shares of MoonLake Immunotherapeutics worth $490K as of Q1 2026.
Dimensional Fund Advisors sold 157,245 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $2.6M.
MoonLake Immunotherapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q1 2026, its #2945 holding.
Dimensional Fund Advisors first reported a position in MoonLake Immunotherapeutics in Q4 2024 and has held it in 6 quarters since.
Dimensional Fund Advisors's MoonLake Immunotherapeutics position peaked at $3.49M in Q4 2024.
147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Dimensional Fund Advisors's 13F filing for Q1 2026, filed 7 May 2026.